
    
      The study period per patient will include 62 weeks treatment, 6 weeks post treatment safety
      follow-up, followed by a long term safety follow-up performed in the form of a phone
      interview at 3, 6, 12, 18 and 24 months from the last administration of the study medication.
    
  